Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Business Development Consultant appointment

3 Jun 2015 08:28

RNS Number : 0577P
Kuala Limited
03 June 2015
 



3 June 2015

Kuala Limited

 

("Kuala" or the "Company")

 

Subscription by Galloway Limited

Appointment of Galloway Limited as Business Development Consultant

 

Kuala Limited ("Kuala"), the AIM listed investment company ("KUL") is pleased to announce the appointment of Galloway Limited ("Galloway") as its Business Development Consultant. Concurrent with its appointment Galloway has subscribed for a 1,439,751 new shares ("Subscription Shares") of the Company at a subscription price of 5.88 pence per share (raising total proceeds of £84,657.37).

 

Appointment of Galloway as Business Development Consultant

 

Kuala, which was recapitalised in November 2014 to evaluate potential acquisition opportunities in the natural resources and/or energy sector, has been evaluating multiple opportunities in the mining and oil & gas industries. However, given the current market conditions and the difficulty of a capital raise in connection with an investment or acquisition opportunity in the natural resources or energy sector, the Directors of the Company have approved the appointment of Galloway as the Company's Business Development Consultant.

 

Under the terms of a consulting agreement dated 2 June 2015 Galloway has agreed to provide procurement and due diligence services to the Company for a fixed period of 6 months in relation to potential investment and/or acquisition opportunities in the bio-tech and fintech sectors. Mr James Mellon is a life tenant of a trust which is the owner of Galloway, and Mr Mellon and Galloway bring considerable investment expertise in the early-stage technology industries.

 

As consideration for its services (and in lieu of all reasonable professional expenses incurred) the Company shall pay to Galloway a fixed fee of £65,278.00. The Company and Galloway Limited have agreed that these fees will be satisfied by the issue of 1,110,170 new shares of the Company to Galloway (the "Consideration Shares"), each with an implied price of 5.88 pence.

 

Should the Company choose to pursue any investment or acquisition outside the scope of its current investing policy (focussed on natural resources and energy) then it would seek to amend its investing policy with the approval of shareholders at a general meeting of shareholders and potentially make appropriate changes to the Board to provide relevant expertise.

 

Galloway is currently conducting technical and financial due diligence on a number of potential investment opportunities for the Company, and has travelled extensively meeting with management teams. Galloway expects to report to the Company on its due diligence conclusions within 60 days. A further announcement in this regard will be made in due course.

 

Subscription by Galloway Limited

 

Under the terms of a subscription letter dated 2 June 2015 Galloway has subscribed for 1,439,751 new shares of the Company at a subscription price of 5.88 pence per share (raising total proceeds of £84,657.37).

 

The subscription by Galloway is at the market price of the Company's ordinary shares on AIM on 8 May 2015 and represents a premium to the market price of the Company's shares on AIM at close of business on 2 June 2015 of 4.5 per cent. The estimated net asset value as at 2 June 2015 is 2.16 pence per ordinary share and therefore the new Subscription Shares are being issued at a premium of 172% to the estimated net asset value.

 

The placing was completed with Galloway concurrently with its appointment as the Company's Business Development Consultant and was regarded as an important step by both parties, underlining Galloway's support for the Company and its management, and its strong belief that the current market conditions present an excellent opportunity for the Company to secure an investment or acquisition opportunity in the near future that will add real shareholder value.

 

Post the allotment of Subscription Shares and Consideration Shares, Galloway will be interested in 4,551,229 ordinary shares representing 14.66% of the enlarged share capital.

 

 

Stephen Dattels, Chairman of Kuala commented:

 

"Market conditions make any investment in mining or oil and gas projects at this time high-risk. Whilst the Company continues to evaluate potential investment and/or acquisition opportunities, the engagement of Galloway, and its subscription, positions the Company to consider and review potential opportunities outside its current investing policy (subject to shareholder approval being received)."

 

Issued Shares

 

The Subscription Shares and the Consideration Shares are expected to be admitted to trading on or around 8 June 2015. Following the issue of the Subscription Shares and the Consideration Shares the number of ordinary shares in issue in the Company will increase to 31,050,939. For the purposes of the Financial Conduct Authority's Disclosure and Transparency Rules ("DTRs"), the issued ordinary share capital of the Company following this allotment consists of 31,050,939 ordinary shares with voting rights attached (one vote per share). There are no shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in, Kuala Limited under the DTRs.

 

Related Party Transaction

Galloway Limited is a significant shareholder in the Company and a related party (as defined by the AIM Rules). The Subscription Shares and the Consideration Shares are on the terms and conditions set out above and Galloway Limited will not be offered any beneficial arrangement.

 

The issue of 1,439,751 Subscription Shares and 1,110,170 Consideration Shares to Galloway Limited constitutes a related party transaction for the purposes of the AIM Rules. The Directors of the Company, having consulted with RFC Ambrian, the Company's nominated adviser, consider the terms of such subscription for shares by Galloway Limited to be fair and reasonable insofar as the shareholders of the Company are concerned.

-ends-

 

For further information please visit www.kualalimited.com or contact:

Kuala Limited

Elysium Fund Management Limited

 

Tel: Tel: +44 1481 810 100

RFC Ambrian Limited (Nomad and Joint Broker)

 Samantha Harrison / Stephen Francavilla

 

Tel: +44 (0) 20 3440 6800 

Peterhouse Corporate Finance Limited (Joint Broker)

Guy Miller / Lucy Williams

 

Tel: +44 (0) 20 7469 0930

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGRGDLIDGBGUX
Date   Source Headline
17th Nov 202010:30 amRNSHolding(s) in Company
12th Nov 20207:00 amRNSInvestee Company Update: Portage Biotech Inc.
5th Nov 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
16th Oct 20209:00 amRNSInvestee Company Update: EMMAC Life Sciences
13th Oct 20207:00 amRNSPlacing and Issue of Equity
23rd Sep 20201:30 pmRNSInvestee Company Update: Yooma Corp.
23rd Sep 20207:00 amRNSHolding(s) in Company
22nd Sep 20207:00 amRNSChange of Broker
17th Sep 20203:45 pmRNSResult of AGM
16th Sep 20204:00 pmRNSInvestee Company Update: Juvenescence Limited
8th Sep 20204:00 pmRNSUpdated Key Information Document
27th Aug 20204:30 pmRNSInvestee Company Update: Factom Inc.
26th Aug 20207:30 amRNSNotice of AGM
26th Aug 20207:00 amRNSFinal Results
25th Aug 20202:30 pmRNSInvestee Company Update: Portage Biotech Inc.
24th Aug 20203:15 pmRNSInvestee Company Update: Leap Gaming
18th Aug 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
5th Aug 20207:00 amRNSInvestee Company Update: Leap Gaming
30th Jul 20208:52 amRNSInvestee Company Update: Factom Inc.
30th Jul 20207:45 amRNSInvestee Company Update: Portage Biotech Inc.
28th Jul 202011:55 amRNSInvestee Company Update: EMMAC Life Sciences
22nd Jul 20201:39 pmRNSInvestee Company Update: EMMAC Life Sciences
14th Jul 202010:15 amRNSInvestee Company Update: Yooma Corp.
13th Jul 20205:01 pmRNSResult of Extraordinary General Meeting
9th Jul 20207:00 amRNSInvestee Company Update: Factom Inc.
6th Jul 202010:31 amRNSInvestee Company Update: Leap Gaming
26th Jun 202012:30 pmRNSNotice of EGM & Proposed Updated Investing Policy
22nd Jun 20207:45 amRNSInvestee Company Update: Leap Gaming
22nd Jun 20207:30 amRNSInvestee Company Update: Leap Gaming
22nd Jun 20207:00 amRNSInvestee Company Update: Factom Inc.
17th Jun 20201:00 pmRNSInvestee Company Update: Portage Biotech Inc.
2nd Jun 20209:30 amRNSInvestee Company Update: Juvenescence Limited
26th May 20207:00 amRNSInvestee Company Update: Portage Biotech Inc
26th May 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
21st May 20207:00 amRNSInvestee Company Update: Leap Gaming
19th May 20207:30 amRNSInvestee Company Update: EMMAC Life Sciences
18th May 20207:00 amRNSInvestee Company Update re Yooma and Board Changes
12th May 202010:15 amRNSInvestee Company Update: Portage Biotech Inc.
6th May 202012:30 pmRNSInvestee Company Update: Portage Biotech Inc.
23rd Apr 20203:15 pmRNSInvestee Company Update: Entertainment Direct Asia
23rd Apr 20207:00 amRNSHolding(s) in Company
16th Apr 20204:15 pmRNSInvestee Company Update: Portage Biotech Inc.
16th Apr 20202:00 pmRNSInvestee Company Update: Portage Biotech Inc.
14th Apr 20207:00 amRNSCorporate Update
2nd Apr 20207:00 amRNSInvestee Company Update: Factom Inc.
1st Apr 20207:00 amRNSInvestee Company Update: Leap Gaming
31st Mar 20201:15 pmRNSInvestee Company Update: EMMAC Life Sciences
20th Mar 20205:04 pmRNSInvestee Company Update: Entertainment Direct Asia
19th Mar 20202:30 pmRNSInvestee Company Update: Factom Inc.
17th Mar 20207:00 amRNSInvestee Company Update: Portage Biotech Inc.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.